Drugs / OM-89
OM-89
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02591901 | Apr 2018 → Aug 2019 | urinary tract infection | Buckinghamshire Healthcare NHS Trust | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06345014 | Dec 2023 → Dec 2025 | chronic pain syndrome, chronic prostatitis | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT04049994 | Jun 2020 → Sep 2023 | spinal cord injury, urinary tract infection | Swiss Paraplegic Research, Nottwil | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06588010 Comparator | Dec 2024 → Dec 2027 expected | cauda equina syndrome with neurogenic bladder | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Phase 3 | NCT00521924 Comparator | Jun 2007 → Apr 2008 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OM 89 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00521924 ↗ |
| Known as | Uro-Vaxom | “Immunomodulation therapy with UroVaxom is a very promising method for the prevention of UTI, however data in individuals with SCI are very limited.” NCT04049994 ↗4“lyophilized lysate of E. coli strains for oral application (Uro-Vaxom®, OM Pharma SA, Meyrin, Switzerland).” PMID 34607600 ↗ Oct 2021 “OM-89 [Uro-Vaxom® Capsule]” NCT06588010 ↗ |
| Known as | Uro-Vaxom Capsule | “OM-89 [Uro-Vaxom® Capsule]” NCT06345014 ↗ |
| Modality | Vaccine | “orally administered, bacterial vaccine” NCT02591901 ↗ |
| Route | Oral | “orally administered” NCT02591901 ↗ |